Enzalutamide (MDV-3100)

An Early Peek At the Phase III PREVAIL Trial of Enzalutamide (Xtandi) Results – Good For Prostate Cancer

An important update from the phase III PREVAIL study (Xtandi in the pre-chemotherapy stage) was released thsi evening (actually yesterday evening) in advance of a formal presentation this Thursday at ASCO GU. The news is good, no the news is great. Last November the trial of Xtandi in men with metastatic castrate resistant prostate cancer [...]

By |2017-10-19T10:48:38-04:00January 29th, 2014|2nd line hormone therapy, Advanced Prostate Cancer, ASCO, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), Uncategorized, Xtandi|0 Comments
Read More

A Statistical Nightmare – Comparing the Efficacy of Zytiga & Xtandi In the Pre-Chemo Setting

Based on the assumption that Enzalutamide (Xtandi) is approved for use in men with castrate resistant metastatic prostate cancer (advanced prostate cancer or mCRPC) who have not had prior chemotherapy, pretty much a foregone conclusion based on the extraordinary phase III Prevail Trial results, including a statistically significant survival advantage of 2.2 months with a [...]

By |2017-10-19T10:49:05-04:00January 23rd, 2014|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, Enzalutamide (MDV-3100), MDV3100, Uncategorized, Understanding APC,